thiophenes has been researched along with Hypertension, Pulmonary in 99 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (1.01) | 18.2507 |
2000's | 65 (65.66) | 29.6817 |
2010's | 32 (32.32) | 24.3611 |
2020's | 1 (1.01) | 2.80 |
Authors | Studies |
---|---|
Callan, E; Entringer, B; Joshi, A; Konduri, GG; Michalkiewicz, T; Parchur, AK; Rana, U; Teng, RJ | 1 |
Eba, S; Hoshikawa, Y; Ishida, K; Kondo, T; Mitsuishi, Y; Moriguchi, T; Okada, Y; Satoh, H; Shimizu, T; Shimokawa, H; Watanabe, T; Yamamoto, M | 1 |
Aung, TH; Foo, D; Francis, PJ; Ho, HH; Huang, W; Ong, PJ; Wong, CP; Yeo, D | 1 |
Catalá-López, F; de la Fuente Honrubia, C; Macías Saint-Gerons, D; Montero, D | 1 |
Benza, RL; Dhaun, N; Hwang, LJ; Liu, X; Naeije, R; Teal, S; Vachiery, JL; Webb, DJ | 1 |
Feng, W; Lin, Y; Lu, H; Xi, AM; Yan, CZ; Zhang, Y | 1 |
Howard, LS; Price, LC | 1 |
Ewert, R; Kirch, W; Opitz, CF; Pittrow, D | 1 |
Badesch, DB; Barst, RJ; Benza, RL; Black, CM; Fleming, TR; Frost, A; Galie, N; Girgis, RE; Highland, KB; Naeije, R; Rubin, L; Strange, C | 1 |
Coghlan, G; Kabunga, P | 1 |
Badesch, DB; Despain, DJ; Dufton, C; Frost, AE; Galie, N; Gerber, MJ; McGoon, MD; McLaughlin, VV; Olschewski, H; Oudiz, RJ; Rubin, LJ | 1 |
Stähler, G | 1 |
Dhaun, N; Goddard, J; MacIntyre, IM; Webb, DJ | 1 |
Faruqi, S; Fathi, H; Morice, AH | 1 |
Champion, HC; Girgis, RE; Hassoun, PM; Hummers, LK; Mathai, SC; Wigley, FM; Zaiman, A | 1 |
Preston, IR; Steiner, MK | 1 |
Beghetti, M; Galiè, N | 1 |
Danesi, R; Dei Cas, L; Lombardi, C; Metra, M; Verzura, G; Zacà, V | 1 |
Gutiérrez, R; Lupi, E; Miranda, MT; Peña, H; Pulido, T; Roquet, I; Rueda, T; Sandoval, J; Santos, E | 1 |
Cacoub, P; Langleben, D | 1 |
Argyropoulou, P; Boutou, AK; Chavouzis, N; Nakou, C; Pitsiou, GG; Stanopoulos, I | 1 |
Mucke, HA | 1 |
Dranitsaris, G; Mehta, S | 1 |
Ghofrani, HA | 1 |
Gaine, SP; Kelleher, B; Lavelle, A; Lawler, G; Mulligan, N; Murphy, DM; Sugrue, R | 1 |
Barton, P; Chen, YF; Fry-Smith, A; Gibbs, JS; Hyde, C; Jowett, S; Malottki, K; Moore, D; Pepke-Zaba, J; Roberts, J | 1 |
Corris, PA; Langleben, D | 1 |
Dalton, B; Gabbay, E; Keogh, A; Steele, P; Stewart, S; Strange, G; Wlodarczyk, J | 1 |
Humbert, M; Montani, D | 1 |
Hunsche, E; Lefebvre, MC | 1 |
Abramowicz, D; Faoro, V; Huez, S; Lamotte, M; Naeije, R; Neupane, S; Retailleau, K | 1 |
Al-Mousily, F; Byrne, BJ; Embury, J; Gannon, KS; Germain, S; Jacques, V; Murray, J; Porvasnik, SL; Shacham, S | 1 |
Coghlan, JG; Denton, CP; Handler, CE; Kabunga, P; Smith, CJ; Valerio, CJ | 1 |
Brimioulle, S; Dewachter, C; Dewachter, L; Fesler, P; Franck, S; Hubloue, I; Kerbaul, F; Naeije, R; Remmelink, M; Rondelet, B | 1 |
Derk, CT; Shetty, N | 1 |
Galiè, N; Gibbs, JS; Hoeper, MM; Simonneau, G | 1 |
Fisher, AJ; Johnson, MK; Kirkham, N; Lee, WT; Lordan, JL; Peacock, AJ | 1 |
Galiè, N; Gibbs, R; Hoeper, MM; Simon, J; Simonneau, G | 1 |
Cima, K; Desole, S; Graziadei, I; Kähler, CM; Vogel, W; Vogelsinger, H | 1 |
Safdar, Z | 1 |
Bauleo, C; Catapano, G; Formichi, B; Genovesi, D; Giuntini, C; Mannucci, F; Marini, C; Michelassi, C; Monti, S; Prediletto, R | 1 |
Delbeck, M; Ellinghaus, P; Kast, R; Laux, V; Nickel, KF; Perzborn, E; Schäfer, S; Schermuly, RT; Strassburger, J; von Degenfeld, G | 1 |
French, B; Gabler, NB; Halpern, SD; Kawut, SM; Liu, Z; Palevsky, HI; Strom, BL; Taichman, DB | 1 |
Bartelds, B; Berger, RMF; Boersma, B; Dickinson, MG; Mohaupt, S; Takens, J; van Albada, M; van Loon, RLE; Wijnberg, H | 1 |
Hwang, LJ; Jardim, C; Jerjes-Sánchez Díaz, C; Kurzyna, M; Pulido, T; Ramírez, A; Sandoval, J; Souza, R; Teal, SA; Torbicki, A | 1 |
Cross, DM; Derzi, M; Horsley, E; Owen, K; Stavros, FL | 2 |
Hintz, E; Klein, R; Staehler, G | 1 |
Blenkhorn, F; Eisenberg, MJ; Fox, B; Hirsch, AM; Joyal, D; Langleben, D; Lesenko, L; Schlesinger, RD | 1 |
Luo, N; Ryan, JJ | 1 |
Fang, X; Fung, ML; Huang, Y; Liu, Y; Mao, G; Shyy, JY; Tian, XY; Wang, N | 1 |
Celermajer, DS; Corte, TJ; Don, GW; Joseph, F | 1 |
Colucci, WS; Givertz, MM; Ooi, H | 1 |
Bibova, J; Hampl, V; Herget, J; Novotna, J; Povysilova, V; Vankova, M | 1 |
Apostolopoulou, SC; Rammos, S | 1 |
Barst, RJ; Dixon, RA; Duncan, B; Frost, A; Frumkin, LR; Hill, N; Horn, EM; Langleben, D; McLaughlin, V; Oudiz, R; Robbins, IM; Shapiro, S; Tapson, VF; Zwicke, D | 1 |
Branzi, A; Galié, N; Manes, A | 1 |
Wilkins, MR | 1 |
Barst, RJ; Hirsch, AM; Langleben, D; Lesenko, L; Shalit, E | 1 |
Barst, RJ; Horn, EM; Widlitz, AC | 2 |
Cheng, J; Liu, C | 1 |
Barst, R; Brock, T; Dixon, R; Langleben, D | 1 |
Barst, RJ; DeMarco, T; Frost, AE; Hill, N; Horn, E; Langleben, D; McLaughlin, V; Oudiz, R; Robbins, IM; Rubenfire, M; Schilz, R; Shapiro, S; Tapson, VF; Zwicke, D | 1 |
Channick, RN; Lee, SH | 1 |
Barst, RJ; Garofano, R; Hansen, JE; Oudiz, RJ; Sun, XG; Wasserman, K; Wu, X | 1 |
Arbak, P; Balbay, O; Comunoğlu, NU; Erbaş, M; Güler, S; Nihat Annakkaya, A; Silan, C; Uzun, O; Yavuz, O | 1 |
Gaine, SP; O'Callaghan, DS | 1 |
Badesch, D; Barst, RJ; Frost, A; Galie, N; Langleben, D; Lawrence, EC; Naeije, R; Shapiro, S | 1 |
Archer, SL; Michelakis, ED | 1 |
Abman, SH | 1 |
Chen, J; Liu, C | 1 |
Coyne, TC | 1 |
Ewert, R; Opitz, CF | 1 |
Humbert, M; Simonneau, G | 1 |
Hoeper, MM | 1 |
Barst, RJ | 1 |
Abubakar, A; Wittbrodt, ET | 1 |
Gomberg-Maitland, M; Jacobs, A; Preston, IR | 1 |
Cortopassi, F; Fernandes, CJ; Jardim, C; Martins, BC; Pulido, T; Sandoval, J; Souza, R | 1 |
Barst, RJ; Benza, RL; Keogh, A; Lawrence, EC; Mehta, S; Oudiz, RJ | 1 |
Brimiouille, S; Fesler, P; Hubloue, I; Huez, S; Kerbaul, F; Naeije, R; Remmelink, M; Rondelet, B; Salmon, I; Vivian, GF | 1 |
Langleben, D | 1 |
Scott, LJ | 1 |
Baloira, A | 1 |
Barst, RJ; Frost, AE; Girgis, RE; Hill, NS; Horn, EM; Langleben, D; McLaughlin, VV; Oudiz, RJ; Robbins, IM; Seibold, JR; Shapiro, S; Tapson, VF | 1 |
Waxman, AB | 1 |
Dhaun, N; Goddard, J; Pollock, DM; Webb, DJ | 1 |
Dinh-Xuan, AT; Hoeper, MM | 1 |
Dupuis, J; Hoeper, MM | 1 |
Amoura, Z; Cacoub, P; Langleben, D | 1 |
Batyraliev, TA; Ekinsi, E; Makhmutkhodzhaev, SA; Pataraia, SA; Pershukov, IV; Preobrazhenskiĭ, DV; Sidorenko, BA | 1 |
Park, MH | 1 |
Biediger, RJ; Blok, N; Bourgoyne, AR; Brock, TA; Bui, H; Chen, Q; Decker, ER; Dixon, RA; Dupré, B; Holland, GW; Knowles, V; Kogan, TP; Lin, S; Market, RV; Raju, B; Wu, C | 1 |
Block, N; Brock, TA; Chen, SJ; Chen, YF; Dixon, RA; Munsch, CL; Sherwood, SJ; Tilton, RG; Wu, C | 1 |
Almany, DK; Crawford, FA; Davis, JN; Fary, DJ; Goldberg, AT; Hendrick, JW; Joffs, C; Spinale, FG; Walker, CA | 1 |
Kim, NH; Rubin, LJ | 1 |
Barst, RJ; Horn, EM; McFarlin, J; McLaughlin, V; Rich, S; Widlitz, A | 1 |
33 review(s) available for thiophenes and Hypertension, Pulmonary
Article | Year |
---|---|
Endothelin receptor antagonists for pulmonary arterial hypertension: rationale and place in therapy.
Topics: Antihypertensive Agents; Bosentan; Clinical Trials, Phase III as Topic; Drug Interactions; Endothelin Receptor Antagonists; Endothelins; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Sulfonamides; Thiophenes | 2008 |
Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endothelin-1; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Phenylpropionates; Pulmonary Artery; Pyridazines; Randomized Controlled Trials as Topic; Sulfonamides; Thiophenes; Treatment Outcome; Vascular Resistance; Walking | 2008 |
Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
Topics: Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Receptors, Endothelin; Scleroderma, Systemic; Sulfonamides; Thiophenes; Treatment Outcome | 2008 |
[Specific drugs for the treatment of pulmonary arterial hypertension - current status].
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Prostaglandins; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; Thiophenes; Vasodilator Agents | 2008 |
Sitaxsentan sodium for pulmonary hypertension.
Topics: Animals; Clinical Trials as Topic; Drug Interactions; Endothelin Receptor Antagonists; Endothelins; Humans; Hypertension, Pulmonary; Isoxazoles; Receptors, Endothelin; Thiophenes | 2008 |
Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.
Topics: Animals; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Patient Compliance; Patient Satisfaction; Phenylpropionates; Pyridazines; Quality of Life; Receptors, Endothelin; Sulfonamides; Thiophenes; Treatment Outcome | 2008 |
Eisenmenger syndrome a clinical perspective in a new therapeutic era of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Eisenmenger Complex; Endothelin Receptor Antagonists; Epoprostenol; Humans; Hypertension, Pulmonary; Isoxazoles; Phosphodiesterase Inhibitors; Piperazines; Pulmonary Circulation; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes | 2009 |
Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas.
Topics: Animals; Antihypertensive Agents; Bosentan; Drug Design; Endothelin Receptor Antagonists; Endothelins; Humans; Hypertension, Pulmonary; Isoxazoles; Patents as Topic; Phenylpropionates; Pyridazines; Sulfonamides; Thiophenes | 2009 |
Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for pulmonary arterial hypertension within their licensed indications: a systematic review and economic evaluation.
Topics: Antihypertensive Agents; Bosentan; Cost-Benefit Analysis; Endothelin Receptor Antagonists; Epoprostenol; Humans; Hypertension, Pulmonary; Iloprost; Isoxazoles; Phosphodiesterase Inhibitors; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; United States; Vasodilator Agents | 2009 |
Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Cohort Studies; Epoprostenol; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Piperazines; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Time Factors; Treatment Outcome | 2010 |
Endothelin receptor antagonists as disease modifiers in systemic sclerosis.
Topics: Animals; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Endothelins; Familial Primary Pulmonary Hypertension; Fibrosis; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Receptors, Endothelin; Scleroderma, Systemic; Sulfonamides; Thiophenes; Treatment Outcome | 2011 |
The endothelin system in pulmonary arterial hypertension.
Topics: Animals; Bosentan; Endothelial Cells; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Humans; Hypertension, Pulmonary; Infant, Newborn; Isoxazoles; Models, Animal; Muscle, Smooth, Vascular; Pulmonary Circulation; Rats; Receptor, Endothelin A; Receptor, Endothelin B; Sulfonamides; Thiophenes | 2004 |
Endothelin receptor antagonists for pulmonary arterial hypertension.
Topics: Adult; Antihypertensive Agents; Bosentan; Child; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Randomized Controlled Trials as Topic; Sulfonamides; Thiophenes | 2005 |
Endothelin antagonism in pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Endothelin-1; Epoprostenol; Humans; Hypertension, Pulmonary; Isoxazoles; Piperazines; Pulmonary Artery; Purines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes | 2005 |
Sitaxsentan: a novel endothelin-A receptor antagonist for pulmonary arterial hypertension.
Topics: Clinical Trials as Topic; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Thiophenes | 2005 |
An evidence-based approach to the management of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Benzamides; Bosentan; Calcium Channel Blockers; Comorbidity; Dichloroacetic Acid; Drug Therapy, Combination; Epoprostenol; Evidence-Based Medicine; Fluoxetine; Humans; Hypertension, Pulmonary; Iloprost; Imatinib Mesylate; Isoxazoles; Phosphodiesterase Inhibitors; Piperazines; Prostaglandins, Synthetic; Pulmonary Artery; Purines; Pyrimidines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Simvastatin; Sulfonamides; Sulfones; Thiophenes; Vasodilator Agents | 2006 |
Pulmonary hypertension in older children: new approaches and therapies.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Antihypertensive Agents; Bosentan; Calcium Channel Blockers; Cardiac Catheterization; Child; Cyclic Nucleotide Phosphodiesterases, Type 5; Echocardiography; Endothelin Receptor Antagonists; Epoprostenol; Humans; Hypertension, Pulmonary; Isoxazoles; Phosphodiesterase Inhibitors; Pulmonary Wedge Pressure; Sulfonamides; Thiophenes; Treatment Outcome | 2006 |
Endothelin receptor antagonists for pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Randomized Controlled Trials as Topic; Sulfonamides; Thiophenes | 2006 |
Dual ET(A)/ET(B) vs. selective ET(A) endothelin receptor antagonism in patients with pulmonary hypertension.
Topics: Antihypertensive Agents; Bosentan; Cell Division; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin Receptor Antagonists; Endothelin-1; Humans; Hypertension, Pulmonary; Isoxazoles; Lung; Pulmonary Fibrosis; Sulfonamides; Thiophenes; Vasoconstriction; Vasodilation | 2006 |
Drug Insight: endothelin-receptor antagonists for pulmonary arterial hypertension in systemic rheumatic diseases.
Topics: Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pulmonary Wedge Pressure; Pyridazines; Rheumatic Diseases; Thiophenes; Treatment Outcome | 2005 |
[Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists].
Topics: Algorithms; Antihypertensive Agents; Bosentan; Drug Interactions; Endothelin Receptor Antagonists; Endothelin-1; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Sulfonamides; Survival Rate; Thiophenes | 2006 |
Sitaxsentan: a selective endothelin-A receptor antagonist, for the treatment of pulmonary arterial hypertension.
Topics: Endothelin A Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Receptor, Endothelin A; Thiophenes | 2007 |
Sitaxsentan for treatment of pulmonary hypertension.
Topics: Animals; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Receptors, Endothelin; Thiophenes; Treatment Outcome | 2007 |
Endothelin receptor antagonism in pulmonary arterial hypertension--a role for selective ET(A) inhibition?
Topics: Clinical Trials as Topic; Endothelin A Receptor Antagonists; Endothelin-1; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Sulfonamides; Thiophenes | 2006 |
Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Randomized Controlled Trials as Topic; Sulfonamides; Thiophenes | 2007 |
Sitaxentan: in pulmonary arterial hypertension.
Topics: Endothelin A Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Randomized Controlled Trials as Topic; Receptor, Endothelin A; Thiophenes; Treatment Outcome | 2007 |
A review of sitaxsentan sodium in patients with pulmonary arterial hypertension.
Topics: Clinical Trials as Topic; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Pulmonary Wedge Pressure; Thiophenes; Treatment Outcome | 2007 |
Selective and mixed endothelin receptor antagonism in cardiovascular disease.
Topics: Animals; Bosentan; Clinical Trials as Topic; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Models, Biological; Sulfonamides; Thiophenes | 2007 |
Endothelin receptor antagonists in pulmonary arterial hypertension.
Topics: Animals; Bosentan; Clinical Trials, Phase III as Topic; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Prognosis; Pyridazines; Randomized Controlled Trials as Topic; Receptor, Endothelin A; Receptor, Endothelin B; Receptors, Endothelin; Severity of Illness Index; Sulfonamides; Survival Rate; Thiophenes; Treatment Outcome | 2008 |
[Treatment of pulmonary arterial hypertension by endothelin receptor antagonists in 2008].
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Sulfonamides; Thiophenes | 2008 |
[Pulmonary hypertension and right ventricular failure. Part XI. Endothelin receptor blockers in the treatment of primary pulmonary arterial hypertension].
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Heart Failure; Hemodynamics; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pyridazines; Sulfonamides; Thiophenes; Ventricular Dysfunction, Right | 2007 |
Advances in diagnosis and treatment in patients with pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Cardiac Catheterization; Disease Progression; Drug Therapy, Combination; Endothelin Receptor Antagonists; Endothelium, Vascular; Epoprostenol; Heart Failure; Humans; Hypertension, Pulmonary; Iloprost; Isoxazoles; Phosphodiesterase Inhibitors; Piperazines; Platelet Aggregation Inhibitors; Prognosis; Pulmonary Artery; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Vasoconstriction | 2008 |
Endothelin in health and disease: endothelin receptor antagonists in the management of pulmonary artery hypertension.
Topics: Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Endothelin Receptor Antagonists; Endothelins; Humans; Hypertension, Pulmonary; Isoxazoles; Pulmonary Artery; Sulfonamides; Thiophenes | 2002 |
17 trial(s) available for thiophenes and Hypertension, Pulmonary
Article | Year |
---|---|
Endothelin antagonism and uric acid levels in pulmonary arterial hypertension: clinical associations.
Topics: Administration, Oral; Adolescent; Adult; Aged; Bosentan; Child; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Prospective Studies; Sulfonamides; Survival Rate; Thiophenes; Time Factors; Treatment Outcome; United States; Uric Acid; Young Adult | 2014 |
Sitaxsentan for the treatment of pulmonary arterial hypertension: a 1-year, prospective, open-label observation of outcome and survival.
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Prospective Studies; Survival Rate; Thiophenes; Time Factors; Treatment Outcome | 2008 |
Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Bosentan; Child; Disease-Free Survival; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Liver Function Tests; Male; Middle Aged; Phenylpropionates; Pyridazines; Sulfonamides; Thiophenes; Transaminases; Treatment Outcome; Young Adult | 2009 |
Interaction of acenocoumarol and sitaxentan in pulmonary arterial hypertension.
Topics: Acenocoumarol; Adolescent; Adult; Anticoagulants; Antihypertensive Agents; Drug Administration Schedule; Drug Interactions; Endothelin Receptor Antagonists; Female; Hemorrhage; Humans; Hypertension, Pulmonary; International Normalized Ratio; Isoxazoles; Male; Prospective Studies; Survival Analysis; Thiophenes; Young Adult | 2009 |
Pulmonary artery pressure limits exercise capacity at high altitude.
Topics: Acute Disease; Adult; Altitude; Blood Pressure; Chronic Disease; Endothelin A Receptor Antagonists; Exercise; Female; Humans; Hypertension, Pulmonary; Hypoxia; Isoxazoles; Kidney; Male; Middle Aged; Oxygen Consumption; Pulmonary Artery; Pulmonary Gas Exchange; Thiophenes; Vascular Resistance; Young Adult | 2010 |
Race and sex differences in response to endothelin receptor antagonists for pulmonary arterial hypertension.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Bosentan; Child; Double-Blind Method; Endothelin Receptor Antagonists; Ethnicity; Exercise Test; Familial Primary Pulmonary Hypertension; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Phenylpropionates; Prevalence; Prospective Studies; Pulmonary Wedge Pressure; Pyridazines; Sex Factors; Sulfonamides; Thiophenes; Treatment Outcome; United States; Walking; Young Adult | 2012 |
Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension.
Topics: Adolescent; Adult; Aged; Blood Pressure; Child; Dose-Response Relationship, Drug; Double-Blind Method; Dyspnea; Endothelin Receptor Antagonists; Endpoint Determination; Female; Humans; Hypertension, Pulmonary; Intention to Treat Analysis; Isoxazoles; Kaplan-Meier Estimate; Liver Function Tests; Male; Middle Aged; Pulmonary Wedge Pressure; Sample Size; Thiophenes; Treatment Outcome; Vascular Resistance; Young Adult | 2012 |
Endothelin mediates increased pulmonary vascular tone in patients with heart failure: demonstration by direct intrapulmonary infusion of sitaxsentan.
Topics: Blood Flow Velocity; Blood Pressure; Endothelin Receptor Antagonists; Endothelins; Female; Heart Failure; Humans; Hypertension, Pulmonary; Infusions, Intra-Arterial; Isoxazoles; Male; Middle Aged; Pulmonary Artery; Pulmonary Circulation; Receptor, Endothelin A; Reference Values; Thiophenes; Vascular Resistance; Vasomotor System; Ventricular Function, Left | 2002 |
Sitaxsentan therapy for pulmonary arterial hypertension.
Topics: Adolescent; Adult; Aged; Anaerobic Threshold; Double-Blind Method; Endothelin Receptor Antagonists; Exercise Test; Exercise Tolerance; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Oxygen Consumption; Thiophenes | 2004 |
STRIDE 1: effects of the selective ET(A) receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials.
Topics: Administration, Oral; Adult; Aged; Antihypertensive Agents; Blood Pressure; Canada; Double-Blind Method; Endothelin A Receptor Antagonists; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Patient Selection; Severity of Illness Index; Thiophenes; Treatment Outcome; United States; Vascular Resistance; Walking | 2004 |
The 6-min walk test (6MW) as an efficacy endpoint in pulmonary arterial hypertension clinical trials: demonstration of a ceiling effect.
Topics: Double-Blind Method; Endothelin Receptor Antagonists; Endpoint Determination; Exercise Test; Heart Diseases; Humans; Hypertension, Pulmonary; Isoxazoles; Research Design; Thiophenes; Walking | 2005 |
Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension.
Topics: Adolescent; Adult; Aged; Clinical Competence; Data Interpretation, Statistical; Endothelin Receptor Antagonists; Exercise Test; Exercise Tolerance; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Oxygen Consumption; Thiophenes; Walking | 2006 |
Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Bosentan; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Dyspnea; Endothelin A Receptor Antagonists; Exercise Test; Exercise Tolerance; Female; Health Status Indicators; Hemodynamics; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Risk Assessment; Sulfonamides; Thiophenes; Treatment Outcome | 2006 |
Sitaxsentan treatment for patients with pulmonary arterial hypertension discontinuing bosentan.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Bosentan; Child; Double-Blind Method; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Sulfonamides; Thiophenes; Treatment Outcome | 2007 |
Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease.
Topics: Adolescent; Adult; Aged; Antihypertensive Agents; Blood Pressure; Cardiac Output; Connective Tissue Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Endothelin A Receptor Antagonists; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Quality of Life; Thiophenes; Treatment Outcome; Vascular Resistance; Walking | 2007 |
Endothelin receptor subtype A blockade selectively reduces pulmonary pressure after cardiopulmonary bypass.
Topics: Analysis of Variance; Animals; Cardiopulmonary Bypass; Disease Models, Animal; Endothelin-1; Hemodynamics; Hypertension, Pulmonary; Isoxazoles; Pulmonary Circulation; Receptors, Endothelin; Swine; Thiophenes; Vascular Resistance; Ventricular Function, Left | 2001 |
Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study.
Topics: Adolescent; Adult; Aged; Child; Endothelin Receptor Antagonists; Exercise Tolerance; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Pilot Projects; Receptor, Endothelin A; Thiophenes | 2002 |
49 other study(ies) available for thiophenes and Hypertension, Pulmonary
Article | Year |
---|---|
AMP-Kinase Dysfunction Alters Notch Ligands to Impair Angiogenesis in Neonatal Pulmonary Hypertension.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Animals, Newborn; Biphenyl Compounds; Ductus Arteriosus; Electron Transport; Endothelial Cells; Enzyme Activation; Female; Hypertension, Pulmonary; Intracellular Signaling Peptides and Proteins; Jagged-1 Protein; Ligands; Lung; Membrane Proteins; Metformin; Mitochondria; Neovascularization, Pathologic; Persistent Fetal Circulation Syndrome; Phosphorylation; Pregnancy; Protein Kinases; Pyrones; Receptors, Notch; Sheep; Thiophenes; Threonine; Transfection | 2020 |
The nuclear factor erythroid 2-related factor 2 activator oltipraz attenuates chronic hypoxia-induced cardiopulmonary alterations in mice.
Topics: Adaptor Proteins, Signal Transducing; Animals; Anticarcinogenic Agents; Cytoskeletal Proteins; Disease Models, Animal; Humans; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Hypoxia; Kelch-Like ECH-Associated Protein 1; Mice; Mice, Knockout; NF-E2-Related Factor 2; Pulmonary Disease, Chronic Obstructive; Pyrazines; Tenascin; Thiones; Thiophenes | 2013 |
Successful treatment of a patient with chronic thromboembolic pulmonary hypertension with rivaroxaban.
Topics: Adult; Anticoagulants; Chronic Disease; Female; Humans; Hypertension, Pulmonary; Morpholines; Pulmonary Embolism; Rivaroxaban; Thiophenes; Treatment Outcome | 2013 |
Endothelin receptor antagonists-induced hepatotoxicity.
Topics: Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Safety-Based Drug Withdrawals; Thiophenes | 2013 |
[The changes of vascular active substances in pulmonary embolism rats and a comparative study of anticoagulant drugs].
Topics: Animals; Anticoagulants; Disease Models, Animal; Endothelin-1; Heparin, Low-Molecular-Weight; Hypertension, Pulmonary; Lung; Morpholines; Pulmonary Embolism; Rats; Rivaroxaban; Thiophenes; Warfarin | 2015 |
Sitaxentan: new drug. Pulmonary hypertension: better to continue to use bosentan.
Topics: Administration, Oral; Drug Approval; Endothelin Receptor Antagonists; Europe; Humans; Hypertension, Pulmonary; Isoxazoles; Randomized Controlled Trials as Topic; Sulfonamides; Thiophenes | 2008 |
Combination of sitaxentan and tadalafil for idiopathic pulmonary arterial hypertension following relapse on bosentan.
Topics: Adult; Antihypertensive Agents; Bosentan; Carbolines; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Sulfonamides; Tadalafil; Thiophenes; Treatment Outcome; Vasodilator Agents | 2010 |
Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.
Topics: Bosentan; Cohort Studies; Comorbidity; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Humans; Hypertension, Pulmonary; Isoxazoles; Lung Diseases, Interstitial; Male; Maryland; Middle Aged; Piperazines; Prognosis; Proportional Hazards Models; Purines; Receptors, Endothelin; Scleroderma, Diffuse; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; Thiophenes; Vasodilator Agents | 2009 |
Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade.
Topics: Endothelin Receptor Antagonists; Follow-Up Studies; HIV; HIV Infections; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Pulmonary Wedge Pressure; Receptors, Endothelin; Thiophenes | 2009 |
A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade.
Topics: Adult; Aged; Antihypertensive Agents; Bosentan; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Liver; Male; Middle Aged; Randomized Controlled Trials as Topic; Sulfonamides; Survival Analysis; Thiophenes; Transaminases; Treatment Outcome | 2009 |
Successful up-front combination therapy in a patient with idiopathic pulmonary hypertension and patent foramen ovale: an alternative to epoprostenol therapy?
Topics: Adult; Antihypertensive Agents; Drug Therapy, Combination; Endothelin A Receptor Antagonists; Epoprostenol; Female; Foramen Ovale, Patent; Humans; Hypertension, Pulmonary; Iloprost; Isoxazoles; Piperazines; Purines; Sildenafil Citrate; Sulfones; Thiophenes; Treatment Outcome; Vasodilator Agents | 2009 |
Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Canada; Costs and Cost Analysis; Drug Costs; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Piperazines; Placebos; Purines; Pyridazines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Treatment Outcome | 2009 |
[Endothelin-receptor antagonists in therapy of pulmonary arterial hypertension].
Topics: Antihypertensive Agents; Bosentan; Cell Proliferation; Endothelial Cells; Endothelin Receptor Antagonists; Endothelium, Vascular; Humans; Hypertension, Pulmonary; Isoxazoles; Sulfonamides; Thiophenes; Vasoconstriction; Vasodilation | 2009 |
Sitaxentan-induced hepatic failure in two patients with pulmonary arterial hypertension.
Topics: Aged; Chemical and Drug Induced Liver Injury; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Thiophenes | 2009 |
The Achilles heel of endothelin receptor therapy for pulmonary arterial hypertension.
Topics: Bosentan; Chemical and Drug Induced Liver Injury; Endothelin Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Liver; Phenotype; Receptors, Endothelin; Sulfonamides; Thiophenes | 2010 |
[Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension].
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Europe; Evidence-Based Medicine; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Piperazines; Practice Guidelines as Topic; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes | 2010 |
Oral Therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
Topics: Administration, Oral; Antihypertensive Agents; Bosentan; Canada; Cost Control; Drug Costs; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Piperazines; Purines; Pyridazines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes | 2010 |
PRX-08066, a novel 5-hydroxytryptamine receptor 2B antagonist, reduces monocrotaline-induced pulmonary arterial hypertension and right ventricular hypertrophy in rats.
Topics: Animals; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Magnetic Resonance Imaging; Male; Monocrotaline; Myocardium; Organ Size; Pulmonary Artery; Pyrimidines; Rats; Rats, Sprague-Dawley; Serotonin 5-HT2 Receptor Antagonists; Thiophenes | 2010 |
Clinical experience with bosentan and sitaxentan in connective tissue disease-associated pulmonary arterial hypertension.
Topics: Aged; Antihypertensive Agents; Bosentan; Clinical Trials as Topic; Connective Tissue Diseases; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Statistics as Topic; Sulfonamides; Thiophenes; Treatment Outcome | 2010 |
Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension.
Topics: Angiopoietin-1; Animals; Bone Morphogenetic Protein Receptors, Type II; Disease Models, Animal; Drug Therapy, Combination; Endothelin Receptor Antagonists; Endothelin-1; Hypertension, Pulmonary; Isoxazoles; Phosphodiesterase 5 Inhibitors; Piperazines; Pulmonary Artery; Pulmonary Circulation; Purines; Sildenafil Citrate; Subclavian Artery; Sulfones; Thiophenes; Treatment Outcome | 2010 |
Liver toxicity of sitaxentan in pulmonary arterial hypertension.
Topics: Chemical and Drug Induced Liver Injury; Contraindications; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Isoxazoles; Liver Failure; Practice Guidelines as Topic; Thiophenes | 2011 |
Sitaxentan-related acute liver failure in a patient with pulmonary arterial hypertension.
Topics: Chemical and Drug Induced Liver Injury; Contraindications; Endothelin A Receptor Antagonists; Familial Primary Pulmonary Hypertension; Fatal Outcome; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Jaundice; Liver Failure, Acute; Piperazines; Purines; Sildenafil Citrate; Sulfones; Thiophenes; Vasodilator Agents; Young Adult | 2011 |
Liver toxicity of sitaxentan in pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Chemical and Drug Induced Liver Injury; Early Termination of Clinical Trials; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Isoxazoles; Safety-Based Drug Withdrawals; Thiophenes | 2011 |
Successful treatment of portopulmonary hypertension with the selective endothelin receptor antagonist Sitaxentan.
Topics: Endothelin Receptor Antagonists; Humans; Hypertension, Portal; Hypertension, Pulmonary; Isoxazoles; Male; Pilot Projects; Syndrome; Thiophenes; Treatment Outcome; Young Adult | 2011 |
Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Drug Substitution; Dyspnea; Edema; Endothelin A Receptor Antagonists; Exercise Test; Exercise Tolerance; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Liver Function Tests; Male; Middle Aged; Natriuretic Peptide, Brain; Oxygen; Phenylpropionates; Pyridazines; Retrospective Studies; Texas; Thiophenes; Time Factors; Treatment Outcome; Walking | 2011 |
Improved survival in patients with inoperable chronic thromboembolic pulmonary hypertension.
Topics: Acid-Base Equilibrium; Aged; Antihypertensive Agents; Blood Gas Analysis; Bosentan; Cardiac Output; Chronic Disease; Drug Therapy, Combination; Exercise Test; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Oxygen Consumption; Oxygen Inhalation Therapy; Piperazines; Purines; Severity of Illness Index; Sildenafil Citrate; Sulfonamides; Sulfones; Survival Rate; Thiophenes; Thromboembolism; Treatment Outcome; Vascular Resistance; Vasodilator Agents | 2013 |
A role for coagulation factor Xa in experimental pulmonary arterial hypertension.
Topics: Animals; Blood Coagulation; Enoxaparin; Factor Xa; Factor Xa Inhibitors; Familial Primary Pulmonary Hypertension; Hemodynamics; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Male; Monocrotaline; Morpholines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Rivaroxaban; Thiophenes; Thrombosis; Warfarin | 2011 |
Mast cell inhibition improves pulmonary vascular remodeling in pulmonary hypertension.
Topics: Animals; Cell Proliferation; Chymases; Cromolyn Sodium; Disease Models, Animal; Heart Ventricles; Hemodynamics; Hypertension, Pulmonary; Lung; Male; Mast Cells; Monocrotaline; Muscle, Smooth, Vascular; Neovascularization, Pathologic; Rats; Rats, Wistar; Sulfonamides; Thiophenes | 2012 |
Evaluation of sitaxentan (Thelin®) toxicity in juvenile rats and regulatory interactions during the development of a European Medicines Agency pediatric investigation plan.
Topics: Animals; Antihypertensive Agents; Behavior, Animal; Child; Dose-Response Relationship, Drug; Drug and Narcotic Control; Endothelin Receptor Antagonists; Europe; Female; Government Agencies; Humans; Hypertension, Pulmonary; Isoxazoles; Male; No-Observed-Adverse-Effect Level; Pediatrics; Rats; Reproduction; Thiophenes; Toxicity Tests | 2012 |
An overview of the preclinical toxicity and potential carcinogenicity of sitaxentan (Thelin®), a potent endothelin receptor antagonist developed for pulmonary arterial hypertension.
Topics: Alkaline Phosphatase; Animals; Antihypertensive Agents; Blood Coagulation; Carcinogenicity Tests; Carcinogens; Chemical and Drug Induced Liver Injury, Chronic; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Endothelin Receptor Antagonists; Erythrocyte Indices; Female; Hypertension, Pulmonary; Hypertrophy; Isoxazoles; Liver; Liver Function Tests; Male; Mice; Mice, Inbred Strains; Organ Size; Rats; Rats, Sprague-Dawley; Risk Assessment; Species Specificity; Thiophenes | 2012 |
Exacerbation of AIH in a patient with an AIH/systemic sclerosis overlap syndrome and pulmonary arterial hypertension treated with the endothelin-1 receptor antagonist sitaxentan.
Topics: Autoantibodies; Autoantigens; Disease Progression; Endothelin A Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Hepatitis, Autoimmune; Humans; Hypertension, Pulmonary; Isoxazoles; Middle Aged; Scleroderma, Systemic; Thiophenes; Treatment Outcome | 2012 |
Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
Topics: Administration, Oral; Aged; Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Middle Aged; Phenylpropionates; Pulmonary Wedge Pressure; Pyridazines; Retrospective Studies; Sulfonamides; Thiophenes; Treatment Outcome; Vascular Resistance | 2013 |
Transitioning between endothelin receptor blockers: monitoring to ensure a smooth transition.
Topics: Bosentan; Endothelin Receptor Antagonists; Familial Primary Pulmonary Hypertension; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Phenylpropionates; Pulmonary Wedge Pressure; Pyridazines; Sulfonamides; Thiophenes; Vascular Resistance | 2013 |
Peroxisome proliferator-activated receptor-γ ameliorates pulmonary arterial hypertension by inhibiting 5-hydroxytryptamine 2B receptor.
Topics: Animals; Familial Primary Pulmonary Hypertension; Hypertension, Pulmonary; Hypoxia; Indoles; Monocrotaline; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; PPAR gamma; Pulmonary Artery; Receptor, Serotonin, 5-HT2B; Rosiglitazone; Serotonin 5-HT2 Receptor Agonists; Thiazolidinediones; Thiophenes; Transcription Factor AP-1; Up-Regulation | 2012 |
Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan.
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Liver; Liver Function Tests; Middle Aged; Phosphodiesterase 5 Inhibitors; Piperazines; Purines; Safety-Based Drug Withdrawals; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes | 2012 |
Metalloproteinase inhibition by Batimastat attenuates pulmonary hypertension in chronically hypoxic rats.
Topics: Animals; Chronic Disease; Collagen; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Hypoxia; Male; Metalloendopeptidases; Phenylalanine; Protease Inhibitors; Pulmonary Circulation; Rats; Rats, Wistar; Specific Pathogen-Free Organisms; Thiophenes | 2003 |
Sitaxsentan in pulmonary arterial hypertension.
Topics: Endothelin Receptor Antagonists; Hemodynamics; Humans; Hypertension, Pulmonary; Isoxazoles; Receptor, Endothelin A; Thiophenes | 2003 |
Selective or nonselective endothelin receptor blockade in pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Endothelin Receptor Antagonists; Exercise Test; Humans; Hypertension, Pulmonary; Isoxazoles; Sulfonamides; Thiophenes | 2004 |
Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension: a 1-year follow-up study.
Topics: Adult; Endothelin Receptor Antagonists; Female; Follow-Up Studies; Hemodynamics; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Thiophenes | 2004 |
Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension.
Topics: Adult; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Middle Aged; Receptor, Endothelin A; Receptor, Endothelin B; Substrate Specificity; Thiophenes | 2004 |
Hypobaric-hypoxia-induced pulmonary damage in rats ameliorated by antioxidant erdosteine.
Topics: Animals; Antibodies, Monoclonal; Antioxidants; Atmosphere Exposure Chambers; Atmospheric Pressure; Endothelial Cells; Hematocrit; Hemorrhage; Hypertension, Pulmonary; Hypertrophy, Right Ventricular; Hypoxia; Immunohistochemistry; Lung; Malondialdehyde; Pulmonary Artery; Random Allocation; Rats; Thioglycolates; Thiophenes | 2006 |
Sitaxsentan: an endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension.
Topics: Endothelin A Receptor Antagonists; Humans; Hypertension, Pulmonary; Isoxazoles; Thiophenes; Treatment Outcome | 2006 |
An evidence-based approach to the management of pulmonary arterial hypertension.
Topics: Antihypertensive Agents; Bosentan; Disease Management; Drug Interactions; Endothelin Receptor Antagonists; Evidence-Based Medicine; Humans; Hypertension, Pulmonary; Isoxazoles; Piperazines; Purines; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Vasodilator Agents; Walking | 2006 |
Effect of sitaxsentan treatment on quality of life in pulmonary arterial hypertension.
Topics: Administration, Oral; Adult; Antihypertensive Agents; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Quality of Life; Thiophenes | 2007 |
Sitaxsentan for the prevention of experimental shunt-induced pulmonary hypertension.
Topics: Anastomosis, Surgical; Angiopoietin-1; Animals; Bone Morphogenetic Protein Receptors; Brachiocephalic Trunk; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Hypertension, Pulmonary; Isoxazoles; Pulmonary Artery; RNA, Messenger; Swine; Thiophenes | 2007 |
[Pulmonary hypertension treatment: future prospects].
Topics: Administration, Intranasal; Administration, Oral; Animals; Bosentan; Drug Evaluation, Preclinical; Endothelin A Receptor Antagonists; Epoprostenol; Forecasting; Humans; Hypertension, Pulmonary; Iloprost; Infusions, Intravenous; Isoxazoles; Life Expectancy; Lung Transplantation; Monocrotaline; Piperazines; Platelet-Derived Growth Factor; Purines; Randomized Controlled Trials as Topic; Rats; Sheep; Sildenafil Citrate; Sulfonamides; Sulfones; Thiophenes; Vasodilator Agents | 2007 |
Pulmonary hypertension: basic concepts and practical management.
Topics: Bosentan; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Isoxazoles; Male; Receptors, Endothelin; Sensitivity and Specificity; Sulfonamides; Survival Analysis; Thiophenes; Treatment Outcome | 2008 |
Endothelin antagonists: substituted mesitylcarboxamides with high potency and selectivity for ET(A) receptors.
Topics: Administration, Oral; Animals; Biological Availability; Drug Evaluation, Preclinical; Endothelin Receptor Antagonists; Half-Life; Hypertension, Pulmonary; Models, Molecular; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptors, Endothelin; Structure-Activity Relationship; Sulfonamides; Thiophenes | 1999 |
Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Hypertension, Pulmonary; Hypertrophy; Hypoxia; Isoxazoles; Male; Monocrotaline; Oxygen; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Thiophenes; Vasoconstriction; Weight Gain | 2000 |